Certolizumab Pego Found To Be Effective New Therapy For Patients With Crohn’s Disease
Mayo Clinic researchers have found that Certolizumab pegol is an effective treatment for adults with Crohn’s disease, according to two new studies. These findings were published in today’s issue of the New England Journal of Medicine. Certolizumab pegol blocks tumor necrosis factor, an important cause of inflammation in Crohn’s disease.Crohn’s disease is an inflammatory disorder of the gastrointestinal tract that affects an estimated 500,000 people in the United States.
